Despite efforts to improve parity in the biomedical workforce, gender bias persists related to equitable pay, promotion, speaking opportunities, journal editorial positions, research funding, and leadership positions. This bias becomes more prominent for women of color and women with other intersectional identities who come from underrepresented groups. It is critical to understand the barriers that women face and why the pathway is especially challenging for women of color. In this commentary, the authors cite research related to the effects of institutional gender bias in academic medicine, including research on bias against women of color. As academic leaders who come from underrepresented groups, the authors are aware that traditional approaches to reducing this bias have not worked well, and they instead highlight promising strategies aimed at filling the pathway to leadership with women of color who are qualified and ready to take the helm. They address solutions to ensure the academic pathway is supportive. They also provide several recommendations, including: offering more opportunities for mentorship and sponsorship; improving access to formal leadership programing; modeling successful upstander initiatives; recognizing the growing role of minority-based medical societies; implementing early career education; increasing journal editorial board representation; and expanding promotion criteria. Appropriate training, education, and partnership with internal and external stakeholders are necessary to advance leadership equity for women of color in academic medicine.Despite efforts to improve parity in the biomedical workforce, gender bias persists related to equitable pay, promotion, speaking opportunities, journal editorial positions, research funding, and leadership positions. This bias becomes more prominent for women of color and women with other intersectional identities who come from underrepresented groups. It is critical to understand the barriers that women face and why the pathway is especially challenging for women of color. In this commentary, the authors cite research related to the effects of institutional gender bias in academic medicine, including research on bias against women of color. As academic leaders who come from underrepresented groups, the authors are aware that traditional approaches to reducing this bias have not worked well, and they instead highlight promising strategies aimed at filling the pathway to leadership with women of color who are qualified and ready to take the helm. They address solutions to ensure the academic pathway is supportive. They also provide several recommendations, including: offering more opportunities for mentorship and sponsorship; improving access to formal leadership programing; modeling successful upstander initiatives; recognizing the growing role of minority-based medical societies; implementing early career education; increasing journal editorial board representation; and expanding promotion criteria. Appropriate training, education, and partnership with internal and external stakeholders are necessary to advance leadership equity for women of color in academic medicine.Copyright © 2022 by the Association of American Medical Colleges
Ook interessant voor je
Veranderende markttrends transformeren hoe farmamarketeers patiënten en zorgverleners vinden, targeten en betrekken
Veranderende markttrends transformeren hoe farmamarketeers patiënten en zorgverleners vinden Uit de Healthcare Marketers Trend Survey blijkt dat er, wat betreft kanaalgebruik, meer groei plaatsvond in nieuwere tactieken...
46 x gelezen
Digitalisering kan zorgsector in 2028 minimaal €1,3 miljard netto opleveren
Digitalisering kan zorgsector in 2028 minimaal €1,3 miljard netto opleveren Digitalisering kan de komende jaren een grote financiële impuls geven aan de gezondheidszorg. Volgens een rapport van strategisch adviesbureau...
72 x gelezen
AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment
Tagrisso approved by FDA for lung cancer treatment The approval followed a Priority Review by the FDA and was based on results from the FLAURA2 phase 3 trial, which were published in The New England Journal of Medicine...
49 x gelezen